{'fraction_non_alphanumeric': 0.03288672350791717, 'fraction_numerical': 0.025578562728380026, 'mean_word_length': 5.682926829268292, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
24-hour activity of lisinopril: clinical advantage in blood pressure control.

We have conducted a multicentre study in patients with mild to moderate hypertension. Lisinopril monotherapy, 10, 20, or 40 mg once daily (n = 35), was compared with captopril monotherapy, 25, 50, or 100 mg twice daily (n = 35). Blood pressure assessments were conducted using both office and 24-hour ambulatory blood pressure monitoring. Area under the curve analysis of ambulatory blood pressure reductions demonstrated significant differences between once-daily lisinopril and twice-daily captopril, with lisinopril producing the most significant reduction in pressure. These therapeutic results reflect the clinical-pharmacological profile of these two angiotensin-converting enzyme inhibitors and provide important clinical implications.